MedTrace Logo

Neoadjuvant Chemotherapy With Cabazitaxel

NCT01941550 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-09-13

No results posted yet for this study

Summary

This study is aimed at evaluating the efficacy regarding the response rate and metastasis-free survival time of cabazitaxel as a neoadjuvant treatment in patients with high risk prostate cancer.

Conditions

  • High-Risk Cancer

Interventions

DRUG

Cabazitaxel chemotherapy

given in 6 cycles

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01941550 on ClinicalTrials.gov